How to incorporate novel therapies into the treatment paradigm for early RRMM?

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked, How to incorporate novel therapies into the treatment paradigm for early relapsed/refractory multiple myeloma (RRMM)?

In this interview, Dr Popat discussed the evolving treatment landscape for early RRMM, highlighting the integration of novel agents, particularly B-cell maturation antigen (BCMA)-directed therapies including belantamab mafodotin. The discussion outlined both the efficacy and toxicities associated with belantamab mafodotin combination regimens, emphasizing the importance of adapted dosing schedules. Popat also discussed strategies for sequencing BCMA-directed therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies.

Hosted on Acast. See acast.com/privacy for more information.